Local Business

Promising COVID-19 treatment sends Seattle biotech company’s stock soaring

Novel Coronavirus SARS-CoV-2 This scanning electron microscope image shows SARS-CoV-2 (orange)—also known as 2019-nCoV, the virus that causes COVID-19—isolated from a patient in the U.S., emerging from the surface of cells (gray) cultured in the lab. Credit: NIAID-RML 1611430

Shares in Seattle biotech firm Omeros shot up more than 60% Monday after a preliminary trial suggested the company's new drug, narsoplimab, could boost survival rates for COVID-19 patients on respirators.

More Headlines